HeartFlow has announced the appointment of Michael Buck as executive vice president and chief commercial officer. Effective immediately, Buck will be responsible for expanding and accelerating global market adoption of the company’s HeartFlow FFRct Analysis, the first noninvasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart.
Buck brings 25 years of operational experience in global business and product development, licensing and acquisitions, venture investment and commercial sales management, according to a company release. He most recently served as president of the medical products division for Cardinal Health, with global responsibility for the Cardinal brand product portfolio. Prior to Cardinal Health, Buck held several senior leadership roles at Abbott Laboratories, including vice president of global market development, vice president of licensing and acquisitions, and vice president of venture investing. He has also held commercial leadership positions at Novoste Corporation, Boston Scientific and Smith & Nephew.
